老年人接种23价肺炎球菌多糖疫苗后对11种非PCV13血清型的功能性免疫应答
本研究纳入≥65岁未接种过肺炎球菌疫苗的老年人,按年龄分为65-74岁组(N=30)和≥75岁组(N=32),接种PPSV23前及接种后4周用多重调理吞噬试验检测11种非PCV13血清型的功能抗体应答。结果显示两组接种后11种血清型GMT均较接种前显著升高,接种后两组间GMT无显著差异。
要点
- PPSV23接种后两组对11种非PCV13血清型的GMT均较接种前显著升高。
- 接种后两组间11种血清型GMT无显著差异。
- 接种后OPA滴度≥8者占93-100%,≥64者占80-100%,≥4倍升高者占9-90%。
核心结论
- PPSV23接种可使老年人对11种非PCV13血清型产生显著的功能性免疫应答。
- MOPA可作为未来评估老年人新型肺炎球菌结合疫苗的有用工具。
研究设计与样本
- 研究纳入≥65岁、未接种过肺炎球菌疫苗的老年人,按年龄分为65-74岁组(N=30)和≥75岁组(N=32)。
- 于PPSV23接种前及接种后4周,用多重调理吞噬试验(MOPA)检测11种肺炎球菌血清型(2、8、9N、10A、11A、12F、15B、17F、20B、22F和33F)的调理吞噬抗体。
主要发现
- 两组接种后11种血清型的OPA几何平均滴度(GMT)均较接种前显著升高。
- 接种后两组间所有血清型的GMT无显著差异。
- 接种后OPA滴度≥8的受试者比例为93-100%,≥64者为80-100%,OPA滴度≥4倍升高者为9-90%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for adults aged ≥65years. To evaluate functional immune response against the additional 11 serotypes that are included in PPSV23, but not the 13-valent pneumococcal conjugate vaccine (PCV13), serotype-specific anti-pneumococcal antibodies were examined using an opsonophagocytic assay (OPA). METHODS: Participants ≥65years of age that were naïve to the pneumococcal vaccine were enrolled. They were divided into two groups according to their age: group 1 (N=30; aged 65-74years) and group 2 (N=32; aged ≥75years). The functional antibody response prior to and 4weeks post-immunization with PPSV23 was determined, using a multiplexed OPA (MOPA) for 11 pneumococcal serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20B, 22F, and 33F). RESULTS: Geometric mean OPA titers (GMTs) to 11 serotypes were significantly increased in both groups post-immunization compared to those prior to immunization. The GMTs for all serotypes were not significantly different between the two groups after immunization. The proportion of subjects with OPA titers post-immunization of ≥8 and ≥64 was 93-100% and 80-100% for the 11 serotypes, respectively, while subjects with a ≥4-fold increase in OPA titers ranged from 9 to 90% for the 11 serotypes. CONCLUSIONS: This study revealed that PPSV23 vaccination induced significant functional immune responses to 11 non-PCV13 serotypes in older adults. The MOPA has been shown to be a useful tool for future application in evaluating new PCVs in older adults. The clinical trial registration number is KCT 0001963 (CRIS, https://cris.nih.go.kr/cris/en/).
引用
- Lee S, Kim HW, Lee JH, et al. Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. Vaccine. 2017. PMID: 28778614. doi:10.1016/j.vaccine.2017.07.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。